Major binary events like late-stage clinical trial results or drug approvals offer high-risk, high-reward opportunities for those who can stomach the uncertainty.
News & Analysis: Immunomedics
Unfortunately, there were more of the latter.
The market isn't pleased with its latest clinical update.
Doctors, researchers, and pharmaceutical experts will converge upon Barcelona to share the latest results in cancer research. Here is a run-down on three to watch.
IMMU earnings call for the period ending June 30, 2019.
IMMU earnings call for the period ending December 31, 2018.
These stocks missed out on the market rally.
The FDA sent the biotech back to the drawing board.
A handful of updates heading into a critical regulatory review date had investors reconsidering a healthy market cap.
The company is inching closer to commercializing its first major product.